Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of Efinopegdutide in Adults With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis
2024-510923-20-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Efinopegdutide with Placebo (2 arms). Primary endpoints: Change from baseline in liver fat content at week 28, Percentage of participants who experienced an adverse event and 1 more. Started Aug 2024; status: completed.
02
Drugs
efinopegdutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2024-510923-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510923-20-00.